These experiments assessed the hemodynamic and aquaretic effects of an arginine vasopressin (AVP) antagonist with dual V1V2-receptor inhibiting properties in rats with congestive heart failure resulting from ischemic cardiomyopathy. The compound d(CH2)5-D-Tyr(Et)VAVP was used in these studies. Rats with limited or extensive myocardial infarcts (i.e., with <50%, or > 66% necrosis of the left ventricular wall, respectively, induced by left coronary ligation) and
A fter a transmural myocardial infarction, the left ventricular wall undergoes progressive stretching and thinning, leading eventually to dilated cardiomyopathy and congestive heart failure (CHF). Several vasoactive neurohormonal factors, including the renin-angiotensin system, the sympathetic nervous system, and arginine vasopressin (AVP), seem to participate in this process and contribute to the hemodynamic and metabolic alterations characteristic of CHF. Extensive investigation of the former two factors during the past few years has led to specific therapeutic interventions such as angiotensin converting enzyme inhibition and a-adrenergic blockade. However, the role of AVP in CHF remains obscure and is a matter of ongoing debate.
Several experimental and clinical studies have shown elevated levels of AVP in decompensated heart failure.1-4 When an antivasopressor V1receptor antagonist of AVP became available for intravenous use in humans, it was shown to produce a hemodynamic improvement with transient decrease in systemic vascular resistance and an increase in cardiac output in those patients in whom plasma AVP levels were elevated. 5, 6 Also, the presence of dilutional hyponatremia has been observed to be one of the markers of severe decompensated CHF.7 8 The treatment of this condition is particularly frustrating because saluretic diuretics tend to further stimulate the inappropriate release of AVP, leading to further retention of free water and aggravation of hypoosmolality. A specific antiantidiuretic V2-receptor antagonist of AVP would offer an additional therapeutic option for this condition by increasing free water clearance with minimal saluretic effect.
The following experiments were designed to study the effects of an AVP antagonist with combined vascular VI-and renal V2-receptor inhibiting properties in rats with CHF resulting from ischemic cardiomyopathy. The AVP antagonist used in this study was the analogue (1-p8-mercapto-,8,,8-cyclopentamethylenpropionic acid)-D-Tyr(O-ethyl)-4-valine-AVP, or d(CH2)5-D-Tyr(Et)VAVP.9
Methods
Male Wistar rats (n=67) weighing 175-200 g (Charles River Laboratories, Kingston, New York) were submitted to myocardial infarction by left cor- onary ligation through a lateral thoracotomy under ether anesthesia and assisted ventilation.10 The ligature was placed between the pulmonary artery and the left atrium, approximately 3 mm from the origin of the left main coronary artery. Mortality in the first 24 hours was 64%.
A single crystal Doppler flow probe (Instrumentation Development Laboratories, Houston, Texas) was placed around the ascending aorta through a midline thoracotomy under anesthetic conditions identical to the above, 5-7 days after the coronary artery ligation. The probe had an inner diameter of 3 mm. Rats were maintained on normal rat chow and water ad libitum. Polyethylene catheters (PE-50, Intramedic, Becton-Dickinson, Parsippany, New Jersey) were inserted in the right iliac artery and the right external jugular vein under light ether anesthesia on the fourth week after coronary ligation and 1 day before the experiment.
Blood pressure and heart rate were recorded with a pressure transducer (Gould-Statham, Gould Electronics, Cleveland, Ohio) connected to the iliac catheter. Doppler frequency in the ascending aorta, reflecting cardiac output (less coronary flow), was continuously assessed by ultrasonic range-gated 10-kHz pulsed Doppler technique."1 The data were recorded on a paper chart recorder (model 3200, Gould Electronics). The Doppler shift is directly proportional to flow changes in the vessel, once the speed of sound and the original frequency of pulse are constants, as are the angle of the crystal and the diameter of the vessel within each animal. The index of total peripheral resistance was derived by dividing mean arterial pressure in millimeters of mercury by the mean Doppler frequency in kilohertz. Blood samples were collected from the arterial catheter for microhematocrit determination on microcentrifuge (Clay-Adams, Becton-Dickinson, Parsippany, New Jersey).
Studies were performed in conscious, unrestrained animals placed in cylindrical plastic cages fitted with urine collection pans, allowing for timed urine collections. Water was freely accessible throughout the study. Blood pressure, heart rate, and Doppler frequency shift were recorded for a 2-hour stabilizing period before the actual initiation of the experiment.
The hemodynamic data, hematocrit levels, and urine output were monitored for a 2-hour baseline period, after which a single dose of the V1V2 vasopressinreceptor antagonist (100 ,gg/kg) was injected through the jugular vein. The recording continued for 4 hours after antagonist administration. Urine output and hematocrit levels were recorded at hourly intervals.
The animals were killed after completion of the experiments, the hearts were removed, and the probes were checked for appropriate fit and placement on the ascending aorta. The infarct size was assessed by macroscopic evaluation of the extent of the fibrotic scar on a section midway between the ligation site and the apex of the heart and expressed as percentage of the left ventricular free wall.
The vasopressin antagonist was dissolved in 5% dextrose in water to a concentration of 100 ,g/ml. Individual doses of 100 ,ug/kg were drawn from this solution.
Statistical evaluation within each group was performed by analysis of variance (ANOVA) for repeated measures, followed, when required, by a Tukey test. Baseline differences between groups were assessed by one-way analysis of variance, and differences in magnitude of change between groups were analyzed through a Mann-Whitney test. Results are expressed as mean+±SEM.
Results
Sixty-seven rats were submitted to coronary ligation. Of these, 43 died within 24 hours, and another three died during the ensuing 4 weeks. Twenty-one rats completed the experiment and were classified in three distinct categories according to the extent of scarring of the left ventricular free wall. Seven rats had no evidence of myocardial damage and were included as sham controls (group 1). Group 2 (n=7) consisted of rats with ischemic damage under 50% of the left ventricular free wall. Group 3 (n =7) was composed of animals in which over 66% of the left ventricular free wall was replaced by scar tissue. Baseline values of Doppler frequency, mean arterial pressure, heart rate, hematocrit level, total peripheral resistance index, and diuresis were not significantly different in the three groups. All groups responded with similar diuresis to hours after injection of the vasopressin inhibitor in the three groups ofrats (sham-operated, limited myocardial infarct, and extensive myocardial infarct). Broken line, urinary flow in a group ofintact untreated rats during the sameperiod ofthe day (9 AM to 3 PM) for comparison. MI, myocardial infarction. the V1V2 antagonist as seen in Table 1 . The consumption of water paralleled the elimination of urine. Figure 1 depicts the urinary flow plotted at hourly intervals for 2 hours before and 4 hours after injection of the V1V2 antagonist. A group of untreated intact normal rats (n =5) whose urine flow was plotted over the same 6 hours (from 9 AM to 3 PM) is shown as reference for comparison. Blood pressure and heart rate were unchanged after the administration of the antagonist to all groups.
Doppler frequency shift was unchanged in groups 1 and 2. However, group 3 showed a significant increase in Doppler shift from baseline to 4 hours, representing an 18% increase in cardiac output (p<0.05 by ANOVA and Tukey test) ( Figure 2 ). Total peripheral resistance index was not statistically altered during the course of the experiment within each group. However, a clear difference in trend was observed between the groups: the group 1 index increased by 13% between time 0 and 4 hours, whereas the group 3 index decreased by 13% (significant difference between the two trends at p<0.05, Mann-Whitney test) ( Figure 3 Finally, hematocrit level was not significantly altered throughout the experiment, with all groups maintaining hematocrit levels in the range of 37-41%.
Discussion
These experiments show that the combined V1V2 vasopressin antagonist has indeed dual action as anticipated. In the sham-operated animals and in those with myocardial infarction comprising less than 50% of the left ventricular wall, the analogue produced a roughly 10-fold increase in diuresis leading to some increase in peripheral vascular resistance with no evidence of significant change in cardiac output. On the other hand, in rats with severely impaired left ventricular function due to extensive myocardial infarction of over 66%, the analogue produced a significant increase in cardiac output and a decrease in peripheral vascular resistance, associated with a roughly fourfold increase in urinary output from baseline. The onset of excessive diuresis was apparent within the first hour after treatment, peaked between 2 and 3 hours, and was still evident after 4 hours. By comparison, normal untreated rats observed during the same period of day (from 9 AM to 3 PM) had a tendency to diminishing urinary flow during their sleep hours.
These data are in accordance with previous studies, which have shown that AVP is stimulated in subjects with severe or decompensated heart failure.'-4 ndeed) it is believed to contribute to both the elevated peripheral vascular resistance and the metabolic abnormalities characteristic of this condition, that is, hypoosmolality with dilutional hyponatremia. The direct vasopressor contribution of AVP is best shown by the increase in peripheral vascular resistance and decrease in cardiac output obtained in patients who were infused with exogenous AVP in amounts sufficient to increase plasma AVP levels by about 50%, which is well within the range found in CHF.12 Treatment with a specific V, antivasopressor antagonist produced a significant temporary improvement in these parame-&l& E E L| ters in 30% of patients, that is, those with elevated AVP levels.5 The metabolic effects are indicated by the dilutional hyponatremia and hypoosmolality that as mentioned earlier can be taken as a marker of the severity of CHF.7 Such effects are also frequently encountered in subjects with severe edema, in whom aggressive diuretic treatment tends to precipitate or further aggravate the metabolic aberrations known as syndrome of inappropriate antidiuretic hormone (SIADH) release, which can present a formidable management problem. The AVP analogue used in the present experiments is a potent antagonist of both the vascular V1and the renotubular V2-receptors. It was synthesized by Manning and coworkers9 and has been shown to block effectively the pressor action of exogenous AVP13 and to produce water diuresis in normal rats by inhibiting endogenous AVP.14 Under normal circumstances, the peripheral V1 activity of AVP does not contribute much to blood pressure maintenance because administration of a V1 antagonist does not produce a fall in blood pressure either in animals15 or in humans.1617 However, it does produce a blood pressure fall if other pressor systems have been inhibited, in which case AVP becomes the predominant mechanism sustaining blood pressure.1819 Therefore, the lack of blood pressure fall in response to the V1V2 antagonist in the present experiments would not be surprising. Despite the marked increase in urine flow, the animals did not become hypovolemic (no evidence of hemoconcentration) as they had free access to water and remained more or less in fluid balance. Interestingly, those with normal or modestly impaired cardiac function had a tendency to increase their peripheral vascular resistance after excessive diuresis, presumably because of activation of reflex mechanisms causing vasoconstriction. Those with extensive myocardial damage showed a decrease in peripheral vascular resistance and concurrent evidence of increased cardiac output in response to the AVP inhibitor, suggesting that activated AVP contributed to the regulation of these parameters, as may be anticipated from previous studies using a pure V1 antagonist of AVP.
Based on experiments in dehydrated animals, Liard20 proposed the possibility that V2 vasodilating receptors exist in the vascular wall. If so, a dual V1V2 antagonist ought to produce a lesser afterload reduction than a selective V1 antagonist. On the other hand, the dual antagonist causes a concurrent preload reduction due to profuse diuresis. The hemodynamic consequences of this contraction in fluid volume would offer an added benefit to the dysfunctional left ventricle, which works against a presumed volume overload, as is usually the case in CHF.
In summary, we have shown that administration of a dual V1V2 antagonist of AVP in rats with markedly impaired left ventricular function produces significant hemodynamic changes and profound water diuresis, without much change in systemic blood pressure. Such treatment, if available, could be of obvious benefit to subjects with CHF.
